01Dec
Americas Antitrust Review 2021
Covid-19 has made 2020 into a year like no other with ‘stay at home’ orders and working from home the new normal. Nonetheless, the tech and pharma industries continued to attract immense antitrust scrutiny, with daily reports in the media and pressure from politicians to address what some perceive to be anticompetitive mergers by digital platforms and pharmaceutical companies, even while innovation in both sectors continues at breakneck speed. In this article, we discuss some of the most...
By:
Cooley LLP
Related
WLG's International Corporate Transactions and Restructuring & Insolvency Resolutions groups review ...
Read More >
On February 18, 2020, the Oregon Department of Revenue (“DOR”) issued draft rule OAR 150-317-1220....
Read More >
While few deals are challenged in Canada, national security reviews are becoming more common and com...
Read More >
Sixteen State legislators from the greater Bay Area took issue with the residential construction lim...
Read More >
On December 20, 2019, President Trump signed into law landmark legislation titled “Setting Every Co...
Read More >
On April 8, 2020, Governor Murphy signed Executive Order No. 122 (the Order) strengthening mitigatio...
Read More >